South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - 10,0 mg - each tablet contains empagliflozin 10,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - 25,0 mg - each tablet contains empagliflozin 25,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - 5,0 mg - each tablet contains vortioxetine hydrobromide equivalent vortioxetine 5,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - 10,0 mg - each tablet contains vortioxetine hydrobromide 10,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - 20,0 mg - each tablet contains vortioxetine hydrobromide equivalent to vortioxetine 20,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - 10,0 mg - each tablet contains rizatriptan benzoate 10, 0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - tablet - 4,0 mg - each tablet contains cyproheptadine hydrochloride equivalent to cyproheptadine 4,0 mg

United States - English - NLM (National Library of Medicine)

a-s medication solutions - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infarc

United States - English - NLM (National Library of Medicine)

a-s medication solutions - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infarc

United States - English - NLM (National Library of Medicine)

a-s medication solutions - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infarc